HC Wainwright Has Optimistic Opinion of Precigen Q4 Earnings

Precigen, Inc. (NASDAQ:PGEN) – HC Wainwright upped their Q4 2026 EPS estimates for shares of Precigen in a research note issued to investors on Thursday, November 5th. HC Wainwright analyst S. Ramakanth now expects that the biotechnology company will post earnings per share of $0.11 for the quarter, up from their previous estimate of $0.06. HC Wainwright currently has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Precigen’s current full-year earnings is $0.23 per share. HC Wainwright also issued estimates for Precigen’s Q1 2027 earnings at $0.13 EPS, Q2 2027 earnings at $0.15 EPS, Q3 2027 earnings at $0.17 EPS and Q4 2027 earnings at $0.19 EPS.

Several other brokerages have also issued reports on PGEN. B. Riley Financial assumed coverage on Precigen in a research note on Friday, September 25th. They issued a “buy” rating and a $12.00 price target on the stock. Citigroup restated a “market outperform” rating on shares of Precigen in a research report on Thursday. Wall Street Zen lowered Precigen from a “strong-buy” rating to a “buy” rating in a research note on Saturday, October 31st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precigen in a research note on Thursday, October 15th. Finally, Zacks Research cut Precigen from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 5th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $13.50.

Precigen Stock Down 16.4%

NASDAQ PGEN opened at $4.22 on Friday. The business has a fifty day moving average price of $7.03 and a two-hundred day moving average price of $5.28. The company has a debt-to-equity ratio of 2.15, a current ratio of 4.58 and a quick ratio of 3.89. Precigen has a fifty-two week low of $3.04 and a fifty-two week high of $8.98. The stock has a market capitalization of $1.50 billion, a PE ratio of 42.20 and a beta of 1.01.

Precigen (NASDAQ:PGEN) last announced its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.02. Precigen had a net margin of 15.55% and a return on equity of 86.42%. The business had revenue of $74.15 million for the quarter, compared to analysts’ expectations of $71.55 million. During the same period last year, the firm posted ($1.06) earnings per share. The firm’s quarterly revenue was up 2437.6% compared to the same quarter last year.

Insider Activity at Precigen

In related news, COO Rutul Shah sold 34,658 shares of the stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $7.50, for a total value of $259,935.00. Following the completion of the transaction, the chief operating officer owned 465,012 shares of the company’s stock, valued at $3,487,590. This represents a 6.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jeffrey Kindler sold 185,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $7.44, for a total transaction of $1,376,400.00. Following the completion of the sale, the director owned 17,100 shares in the company, valued at $127,224. This represents a 91.54% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 235,000 shares of company stock valued at $1,751,400. 41.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Precigen

Hedge funds have recently modified their holdings of the company. Corient Private Wealth LP bought a new stake in shares of Precigen in the 2nd quarter valued at $1,908,000. The Manufacturers Life Insurance Company bought a new stake in shares of Precigen in the 2nd quarter worth $519,000. Bank of New York Mellon Corp bought a new stake in shares of Precigen in the 2nd quarter worth $2,705,000. Bank of America Corp DE bought a new position in shares of Precigen during the second quarter valued at about $10,536,000. Finally, Squarepoint Ops LLC increased its stake in Precigen by 462.8% in the 2nd quarter. Squarepoint Ops LLC now owns 353,272 shares of the biotechnology company’s stock valued at $2,014,000 after buying an additional 290,505 shares during the last quarter. Institutional investors and hedge funds own 33.51% of the company’s stock.

Key Precigen News

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: HC Wainwright raised its EPS estimates for every quarter from Q4 2026 through Q4 2027, including its Q4 2027 forecast to $0.19 from $0.14. The firm reiterated its Buy rating and $18 price target, signaling increased confidence in expected earnings. Precigen stock coverage
• Positive Sentiment: Precigen reported PAPZIMEOS revenue of $72.9 million in Q3, up 37% sequentially, and said it generated positive cash flow a quarter ahead of guidance. The company also reported $35.8 million in net income and received FDA Platform Technology Designation for its AdenoVerse platform. Q3 results and business update
• Positive Sentiment: Citizens JMP raised its price target to $12 from $11 and maintained a Market Outperform rating, citing a higher PAPZIMEOS sales outlook after the quarterly update. Citizens JMP price-target coverage
• Neutral Sentiment: Q3 EPS was $0.08. That topped the $0.06 consensus cited by some coverage, but fell short of the $0.09 estimate cited by Zacks, making the earnings comparison mixed. Revenue of $74.15 million exceeded the $71.55 million estimate. Zacks Q3 earnings coverage

About Precigen

Precigen, Inc is a clinical-stage biotechnology company focused on developing gene and cell therapies for cancer and serious diseases. The company uses its proprietary UltraCAR-T, AdenoVerse, and other gene-engineering platforms to design potential treatments intended to improve the targeting, persistence, and manufacturing of therapeutic cells and genetic medicines.

Precigen’s pipeline has included PRGN-2012, an investigational immunotherapy based on a gorilla adenovector for recurrent respiratory papillomatosis, as well as PRGN-2001, an investigational HPV-targeted immunotherapy.